Peptide library

Thymosin alpha 1
(thymalfasin)

A 28-amino-acid peptide first isolated from the thymus in 1977 and sold abroad as Zadaxin. Where it is approved and for what, what the controlled trials found, what regulators said about safety, and where it stands in November 2026.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

Thymosin alpha 1, or thymalfasin, is a 28-amino-acid peptide first isolated from calf thymus in 1977. Italy authorises it, as Zadaxin, as an adjuvant to flu vaccination in people with weakened immune systems; it is not FDA-approved. Placebo-controlled trials in hepatitis B (1999) and sepsis (2025) found no significant effect on their primary outcomes.

Key takeaways

  • Thymosin alpha 1 is a 28-amino-acid peptide found naturally in the body; thymalfasin is the synthetic version, with the same sequence.
  • Italy authorises it as Zadaxin, an adjuvant to flu vaccination in people with weakened immune systems; FDA’s 2024 review also cites approvals in India and Hong Kong.
  • Placebo-controlled trials in chronic hepatitis B (n=97, 1999) and sepsis (n=1,106, 2025) showed no statistically significant effect on their primary outcomes.
  • FDA’s review notes it was well tolerated in most clinical studies, but concluded its use in compounding may raise safety concerns, including a risk of immune reactions against the peptide.
  • It is not FDA-approved; FDA’s advisory committee voted 17 to 4 against adding it to the 503A bulks list, and WADA’s 2026 and 2027 Lists do not name it.

01Thymosin alpha 1 at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionThymosin alpha 1
What it isA 28-amino-acid peptide with an acetyl group at its starting end, Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, molecular weight 3,108.3 g/mol. It occurs naturally in the body and was first isolated from calf thymus in 1977.
Other namesThymosin α1, Ta1. Thymalfasin is the synthetic version, with the same sequence. Zadaxin is a finished medicine sold in some countries.
Evidence tierT1 in hepatitis B and sepsis, with no significant effect on the primary outcome in the two trials below. T3 and T4 for how it acts.
Human studiesPlacebo-controlled trials include n=97 (chronic hepatitis B, 1999) and n=1,106 (sepsis, 2025). FDA’s 2024 review of 13 uses found the evidence lacking for all.
United StatesNot FDA-approved. FDA’s compounding advisory committee voted 17 to 4 against adding it to the 503A bulks list (4 Dec 2024). Not one of the six peptides in HHS’s October 2026 compounding policy.
Italy and the EUAuthorised in Italy as Zadaxin, prescription only, as an adjuvant to flu vaccination in people with weakened immune systems. An EU orphan designation for liver cancer is not an authorisation.
United KingdomNo results for thymalfasin, thymosin alpha or Zadaxin on the emc medicines database (18 Nov 2026).
AustraliaNot named in the Poisons Standard October 2026; its only thymosin entry is thymosin β4 (text searched 18 Nov 2026).
WADANot named on the 2026 or 2027 Prohibited List.

02What is thymosin alpha 1?

Thymosin alpha 1 is a peptide of 28 amino acids with an acetyl group on its first amino acid. FDA’s 2024 review describes it as physiologically present in the human body, and as first isolated in 1977 from thymosin fraction 5, a crude extract of calf thymus. Thymalfasin is the chemically synthesised version, identical in sequence. Zadaxin is a finished medicine, which FDA says is not interchangeable with the substance.

In cell and animal studies summarised by FDA, its effects on the immune system are attributed to activation of toll-like receptors, sensors on dendritic cells and early lymphoid cells (T4 and T3). FDA adds that the clinical relevance is hard to define, partly because most animal studies used amounts far above those in human trials.

The shared name misleads. Thymosin β4, the protein behind TB-500, is a different molecule of 43 amino acids with a different sequence: see our TB-500 guide.

03What do the human trials of thymosin alpha 1 show?

Thymosin alpha 1 has been tested against placebo in people, including in the two trials below.

Chronic hepatitis B, 1999 (T1). A phase III, multicentre, randomised, double-blind trial enrolled 97 adults, 49 given thymosin alpha 1 and 48 placebo. A complete response, meaning virus undetectable on repeat tests and a marker of active infection negative at 12 months, occurred in 14% versus 4% (P=0.084), which is not statistically significant. The authors wrote that the results “do not confirm observations of treatment efficacy reported in other clinical studies”. FDA calls it the only double-blind trial of thymosin alpha 1 alone against placebo in hepatitis B, and says it “failed to demonstrate the efficacy”.

Sepsis, 2025 (T1). The TESTS trial randomised 1,106 adults with sepsis at 22 centres in China between 2016 and 2020, and analysed 1,089. Death from any cause within 28 days occurred in 23.4% of the thymosin alpha 1 group and 24.1% of the placebo group (hazard ratio 0.97, 95% CI 0.76 to 1.24, as corrected in May 2025). The authors found “no clear evidence” that it lowered 28-day mortality, and no secondary outcome differed significantly. Funders included SciClone Pharmaceuticals, the maker of Zadaxin; the authors state the funders had no role in design, data collection or interpretation.

FDA’s 2024 review. Before TESTS was published, FDA reviewed 13 uses, from hepatitis B and C to three cancers, sepsis and flu-vaccine response. It concluded there is “a lack of evidence to support the effectiveness” for all of them, with studies “limited by small sample sizes and design deficiencies”. On flu vaccines, the use Italy authorises, it found the evidence insufficient to reach a conclusion. How we grade evidence: evidence grades.

04What have regulators said about thymosin alpha 1 safety?

FDA has reviewed its trial record and still raises specific concerns.

FDA. FDA’s 2024 review says that “in most clinical studies, Ta1 has been found to be well-tolerated”, with local irritation, redness or discomfort where it was injected as the most common reaction. In the same review, FDA concluded that its use in compounding “may raise safety concerns”: as a 28-amino-acid peptide given by injection it “may pose a significant risk for immunogenicity”, an immune reaction against the peptide itself, made more likely by aggregation and impurities. FDA’s compounding page adds that “the safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.”

Specific uses. FDA’s review also says it is not clear whether thymosin alpha 1 could lead to or worsen graft-versus-host disease, or engraftment failure, in stem-cell transplant patients, and that safety data are insufficient to evaluate its use with flu vaccines licensed in the US. It notes that Zadaxin’s label in Indonesia describes transient rises in liver enzymes.

Reports. FDA’s search of FAERS, its adverse-event database, found one US report through 10 June 2024: a trial participant also receiving peginterferon, hospitalised with atrial fibrillation and anxiety. FDA says interpreting cause is confounded by peginterferon, whose label lists those events.

The Italian label. Zadaxin’s label rules it out in pregnancy and breastfeeding, says it should not be used in children, advises caution in people prone to allergies or with past allergic reactions, and asks for case-by-case assessment in autoimmune disease.

The sepsis trial. In TESTS, no safety outcome differed significantly between groups. All of this concerns regulated products in trials, not products sold online. How to read safety claims: side effects, documented vs unknown.

05Where is thymosin alpha 1 approved? Status by country

United States. Thymosin alpha 1 is not FDA-approved, and FDA’s 2024 review states it is not a component of any FDA-approved drug. After a nomination to add it to the 503A bulks list was withdrawn, FDA reviewed it on its own initiative and recommended against listing. On 4 December 2024, its compounding advisory committee voted 17 to 4 against each of its two forms. FDA’s compounding page lists it among substances previously in category 2 whose nominations were withdrawn. It appears in neither part of 21 CFR 216.23: substances added to the list, or excluded from it. It is not one of the six peptides in HHS’s October 2026 policy. Background: FDA’s peptide categories.

Italy. Italy’s medicines agency, AIFA, lists Zadaxin (timosina alfa 1) as authorised since 1996, prescription only and marketed. Its label gives one indication: an adjuvant to flu vaccination in people with weakened immune systems. Products sold online as thymosin alpha 1 are not that medicine.

Elsewhere. FDA’s review, citing national regulator records, lists approval in India for chronic hepatitis B in adults with compensated liver disease and active viral replication, and in Hong Kong, and cites monographs from Singapore and Mexico. Of a manufacturer’s wider claims of approvals across four world regions, FDA writes that it was “unable to independently verify” them. In the EU, FDA notes an orphan designation for liver cancer; orphan designation is not a marketing authorisation.

United Kingdom. Searches of the emc medicines database for thymalfasin, thymosin alpha and Zadaxin returned no results on 18 November 2026. More: are peptides legal in the UK?

Australia. Thymosin alpha 1 is not named in the Poisons Standard October 2026, whose only thymosin entry is thymosin β4. Other Australian rules on unapproved peptide products: are peptides legal in Australia?

Sport. It is not named on WADA’s 2026 or 2027 Prohibited List. Athletes should check with their national anti-doping organisation: see peptides and anti-doping.

06What doesn’t thymosin alpha 1 research show?

  • Any effect in healthy people. The trials above enrolled people with hepatitis B or sepsis, and FDA’s 2024 review covered uses in disease or in a weakened response to vaccines.
  • Whether older positive reports hold up. FDA notes many hepatitis B studies used far less sensitive virus tests, and comparison treatments no longer preferred.
  • The immune-reaction risk of products made outside regulated manufacturing. FDA says the safety information is inadequate to judge it.
  • What a vial sold online under the name contains. Only a lab report on that vial’s own lot can show it, and only for what the lab tested: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA evaluation of thymosin alpha-1 (Ta1)-related bulk drug substances, briefing document for the Pharmacy Compounding Advisory Committee meeting of 4 December 2024. Advisory committee briefing, dated 15 Nov 2024 (pp. 7–10, 18–22, 29–38, 43–50, 79–80, 106–107, 116–120); read 18 Nov 2026. www.fda.gov/media/183820/download
  2. U.S. Food and Drug Administration. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, 4 December 2024. Minutes approved 21 Feb 2025 (pp. 7–8); read 18 Nov 2026. www.fda.gov/media/185642/download
  3. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  4. Code of Federal Regulations, 21 CFR 216.23: bulk drug substances that can be used to compound drug products in accordance with section 503A. eCFR, up to date as of 16 Nov 2026; read 18 Nov 2026. www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-21…
  5. Agenzia Italiana del Farmaco (AIFA). Banca dati farmaci: Zadaxin (timosina alfa 1), with its summary of product characteristics made available on 26 Feb 2026. Italian medicines database record; read 18 Nov 2026. medicinali.aifa.gov.it/it/#/it/dettaglio/0000022315
  6. Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat, 1999;6(5):397–403. PMID 10607256. pubmed.ncbi.nlm.nih.gov/10607256/
  7. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 2025;388:e082583. PMID 39814420; full text PMC11780596. Figures on this page are as corrected on 30 May 2025 (BMJ 2025;389:r1098, PMID 40447307). pubmed.ncbi.nlm.nih.gov/39814420/
  8. emc (electronic medicines compendium). Searches for “thymalfasin”, “thymosin alpha” and “Zadaxin”: no results. UK database of licensed medicines; searched 18 Nov 2026 (control search “somatropin”: 21 results). www.medicines.org.uk/emc/search?q=thymalfasin
  9. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  10. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is thymosin alpha 1 FDA-approved?

No. FDA’s 2024 review states it is not a component of any FDA-approved drug, and FDA’s compounding advisory committee voted 17 to 4 against adding it to the list of substances US pharmacies may compound with.

Where is thymosin alpha 1 approved?

Italy authorises it as Zadaxin, as an adjuvant to flu vaccination in people with weakened immune systems. FDA’s 2024 review also cites approval in India for chronic hepatitis B, and in Hong Kong. Products sold online as thymosin alpha 1 are not those medicines.

Is thymosin alpha 1 the same as thymosin beta 4 or TB-500?

No. Thymosin alpha 1 has 28 amino acids; thymosin β4 is a different protein of 43, and TB-500 usually means a seven-amino-acid fragment of thymosin β4, though products sold under that name vary.

What did the sepsis trial of thymosin alpha 1 find?

The TESTS trial of 1,106 adults in China found 28-day mortality of 23.4% with thymosin alpha 1 and 24.1% with placebo, a difference that was not significant. The authors found no clear evidence that it lowered mortality.

Is thymosin alpha 1 banned in sport?

It is not named on WADA’s 2026 or 2027 Prohibited List. Athletes should check any substance with their national anti-doping organisation.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page